Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Aptinyx Presents Preclinical Data on NMDA Receptor Modulator NYX-2925 at the International Association for the Study of Pain’s 17th World Congress on Pain


Posted on: 14 Sep 18

EVANSTON, Ill., Sept. 14, 2018 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the presentation of two posters highlighting preclinical data on novel N-methyl D-aspartate (NMDA) receptor modulator, NYX-2925, that support its ongoing clinical development for the treatment of chronic pain conditions. Results from the preclinical studies will be presented at the International Association for the Study of Pain’s (IASP) 17th World Congress on Pain in Boston. 

“These compelling preclinical data observed in the course of our ongoing research and discovery efforts demonstrate strong mechanistic support for developing NYX-2925 as a potential therapy for chronic pain conditions, in which synaptic plasticity processes are known to be disrupted,” said Cassia Cearley, PhD, vice president of research at Aptinyx. “These data show that NYX-2925 has the potential to address not only the pain, but also the emotional and cognitive impairments that often result from synaptic plasticity disruption.”

NYX-2925 has demonstrated robust activity in preclinical models of numerous neuropathic pain conditions with a favorable tolerability profile. In a Phase 1 clinical study in healthy human subjects, NYX-2925 was well tolerated across a wide dose range, including dose levels well in excess of the expected therapeutic levels. NYX-2925 is currently in Phase 2 clinical development for the treatment of painful diabetic peripheral neuropathy (DPN) and is also being evaluated in an exploratory Phase 2 study in fibromyalgia. The U.S. Food and Drug Administration has granted Fast Track designation to Aptinyx’s development of NYX-2925 for the treatment of neuropathic pain associated with DPN. 

Presentation Details:

Presentation Title: NYX-2925 Improves Both Pain and Its Affective States in the Rat Chronic Constriction Injury Model of Neuropathic Pain (Poster Number: PSN180)
Presenter: Nayereh Ghoreishi-Haack, Aptinyx
Poster Presentation: Sunday, September 16 at 9:30 a.m. ET

Presentation Title:
NYX-2925, a Novel NMDA Receptor Modulator, Re-Normalizes Synaptic-Plasticity Associated Cortical Protein Expressions in Rats with Chronic Constriction Nerve Injury (Poster Number: PSN114)
Presenter: Gladys Morrison, Ph.D., Aptinyx
Poster Presentation: Sunday, September 16 at 9:30 a.m. ET

About Aptinyx
Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders. Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulate – rather than block or over-activate – NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication. The company has three product candidates in clinical development in central nervous system indications, including chronic pain, post-traumatic stress disorder (PTSD), and cognitive impairment associated with Parkinson’s disease. Aptinyx is also advancing additional compounds from its proprietary discovery platform, which continues to generate a rich and diverse pipeline of small-molecule NMDA receptor modulators with the potential to treat an array of neurologic disorders. For more information, visit www.aptinyx.com.

Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding our business plans and objectives, expectations regarding the design, implementation, enrollment, timing and success of our clinical trials and planned clinical trials, expectations regarding our preclinical development activities, and expectations regarding our uses of capital, expenses. Risks that contribute to the uncertain nature of the forward-looking statements include: the success, cost and timing of our product candidate development activities and planned clinical trials; our ability to execute on our strategy; regulatory developments in the United States and foreign countries; our estimates regarding expenses, future revenue and capital requirements; as well as those risks and uncertainties set forth in our most recent quarterly report on Form 10-Q and in our other filings and reports with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Aptinyx undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Investor Contacts:
Nick Smith
Aptinyx Inc.
ir@aptinyx.com
847-871-0377

Rachel Frank
Stern Investor Relations
rachelf@sternir.com
212-362-1200

Media Contact:
Jordann Phillips
Canale Communications
jordann@canalecomm.com
619-849-6009

 

GlobeNewswire
globenewswire.com

Last updated on: 17/09/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.